Voriconazole for Fungal Infections (Vfend)
Complete guide to Voriconazole (Vfend): uses, dosage, side effects, and important precautions for treating serious fungal infections.
What is Voriconazole (Vfend)?
Voriconazole is a broad-spectrum, triazole antifungal agent prescribed to treat serious fungal infections within the body. The medication is marketed under the brand name Vfend and is available in multiple formulations including oral tablets (50 mg or 200 mg), oral suspension (40 mg/ml), and powder for intravenous infusion. This medication belongs to the triazole class of antifungals and works by disrupting the formation of ergosterol, an essential component of fungal cell membranes. Without a functional cell membrane, the fungus is killed or prevented from spreading.
Indications and Uses
Voriconazole is indicated for the treatment of adults and children aged 2 years and above with various serious fungal infections. The primary indications include:
- Treatment of invasive aspergillosis (fungal infection in the lungs)
- Treatment of candidaemia in non-neutropenic patients
- Treatment of fluconazole-resistant serious invasive Candida infections, including C. krusei
- Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.
- Prophylaxis in patients at high risk of developing invasive fungal infections, such as allogeneic haematopoietic stem cell transplant (HSCT) recipients
In clinical trials, voriconazole demonstrated superior efficacy compared to amphotericin B. For invasive aspergillosis treatment, 53% of patients responded to voriconazole compared to 31% with amphotericin B, and survival rates were significantly greater with voriconazole. For candidaemia, the percentage of treatment responders was equivalent at 72% for both voriconazole and comparator treatments.
How to Take Voriconazole
Voriconazole should be taken as prescribed by your healthcare provider. The standard dosing regimen involves taking two doses per day, twelve hours apart. Treatment should be initiated with an intravenous regimen, with transition to an oral regimen when clinically appropriate. The duration of therapy depends on the type and severity of the fungal infection being treated.
For prophylaxis, therapy should be initiated on the day of transplant and may be administered for up to 100 days, with potential continuation up to 180 days after transplantation in cases of continuing immunosuppression or graft-versus-host disease (GvHD).
Dosage Information
Voriconazole dosing is tailored based on patient age, weight, and clinical condition. The recommended dosing regimen varies between treatment and prophylaxis scenarios, with specific dosing protocols for different age groups, including children aged 2 to less than 12 years and adolescents aged 12 to less than 17 years. Serum creatinine levels should be closely monitored, particularly in patients receiving intravenous formulations.
In patients with hepatic impairment, the standard loading dose regimens should be used, but maintenance doses should be halved in patients with mild to moderate hepatic cirrhosis (Child-Pugh A and B). No dose adjustment is necessary in patients with acute hepatic injury manifested by elevated liver function tests.
Important Precautions and Warnings
Before taking voriconazole, inform your healthcare provider about any existing medical conditions and medications you are currently taking. Several important precautions and warnings apply:
Hepatic Function Monitoring
Serious hepatic reactions, including clinical hepatitis, cholestasis, and fulminant hepatic failure, have been uncommonly reported during voriconazole treatment. These reactions occurred primarily in patients with serious underlying medical conditions, predominantly hematological malignancy. However, hepatic reactions including hepatitis and jaundice have also occurred in patients with no other identifiable risk factors. Liver dysfunction has usually been reversible upon discontinuation of therapy. Patients receiving voriconazole must be carefully monitored for hepatic function, with laboratory evaluation required before treatment initiation and at least weekly during the first month of treatment. If treatment is continued beyond the initial period, monitoring frequency can be reduced to monthly if liver function tests show no changes.
Renal Function Monitoring
Acute renal failure has been observed in patients undergoing treatment with voriconazole. Patients being treated with voriconazole are likely to be treated concurrently with nephrotoxic medications and may have concurrent conditions that result in decreased renal function. Patients should be monitored for the development of abnormal renal function through laboratory evaluation of serum creatinine. Voriconazole is hemodialysed with a clearance of 121 mL/min, but a four-hour hemodialysis session does not remove sufficient voriconazole to warrant dose adjustment.
Infusion-Related Reactions
During infusion of the intravenous formulation of voriconazole in healthy subjects, anaphylactoid-type reactions, including flushing, fever, sweating, tachycardia, chest tightness, dyspnea, faintness, nausea, pruritus, and rash, have occurred uncommonly. Symptoms appear immediately upon initiating the infusion, and consideration should be given to stopping the infusion should these reactions occur.
Cardiac Precautions
Voriconazole should be administered with caution to patients with potentially proarrhythmic conditions, including congenital or acquired QTc prolongation, cardiomyopathy (particularly when heart failure is present), sinus bradycardia, existing symptomatic arrhythmias, and concomitant medication known to prolong the QTc interval. Electrolyte disturbances such as hypokalemia, hypomagnesemia, and hypocalcemia should be corrected prior to initiation of and during voriconazole therapy.
Pancreatitis Risk
Pancreatitis has been observed in patients undergoing treatment with voriconazole. Patients with risk factors for acute pancreatitis, such as recent chemotherapy or hematopoietic stem cell transplantation, should be monitored for the development of pancreatitis during voriconazole treatment.
Photosensitivity and Skin Reactions
Voriconazole can cause serious photosensitivity reactions. Patients should immediately contact their healthcare provider for new or worsening skin rash. If a patient develops a rash, they should be monitored closely, and voriconazole should be discontinued if lesions progress.
Skeletal Issues
Fluorosis and periostitis have been reported during long-term voriconazole therapy. If a patient develops skeletal pain and radiologic findings compatible with fluorosis or periostitis, voriconazole should be discontinued.
Adrenal Insufficiency
Reversible cases of adrenal insufficiency have been reported in patients receiving voriconazole. Patients on long-term treatment with voriconazole and corticosteroids (including inhaled corticosteroids) should be monitored carefully.
Drug Interactions
Voriconazole can interact with numerous medications, potentially altering their concentrations or effectiveness. Important contraindicated combinations include coadministration with efavirenz at standard doses, as efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects, and voriconazole also significantly increases efavirenz plasma concentrations. Additionally, coadministration with high-dose ritonavir (400 mg and above twice daily) is contraindicated because ritonavir significantly lowers voriconazole concentrations.
Voriconazole should be administered with caution in patients taking concomitant medication known to prolong the QTc interval, particularly when there is also a potential for voriconazole to increase plasma concentrations of such medications. Always consult your healthcare provider or pharmacist before taking any new medications while on voriconazole to avoid potentially dangerous interactions.
Side Effects and Adverse Reactions
Like all medications, voriconazole can cause side effects. Common side effects may include visual disturbances, photosensitivity, and skin reactions. More serious adverse reactions, though uncommon, may include hepatic dysfunction, renal impairment, cardiac arrhythmias, pancreatitis, and adrenal insufficiency. Some patients may experience anaphylactoid-type reactions during intravenous infusion.
If you experience any unusual symptoms or side effects while taking voriconazole, contact your healthcare provider immediately. Do not discontinue the medication without consulting your doctor, as abrupt cessation may be harmful.
Patient Management and Monitoring
Proper patient management while on voriconazole includes regular laboratory evaluation of renal function (particularly serum creatinine) and hepatic function (particularly liver function tests and bilirubin). Electrolyte levels should be monitored and corrected as necessary. Your healthcare provider will determine the appropriate monitoring schedule based on your individual circumstances and risk factors.
Special Populations
Voriconazole is approved for use in adults and pediatric patients aged 2 years and above. Dosing recommendations for pediatric patients are based on population pharmacokinetic analysis in immunocompromised children and adolescents. Patients with hepatic impairment require dose adjustments, while those with renal impairment should generally be administered oral voriconazole rather than intravenous formulations, as the intravenous vehicle sulfobutylether-cyclodextrin sodium (SBECD) occurs in the intravenous formulation.
Frequently Asked Questions
Q: How often should I take voriconazole?
A: Voriconazole is typically taken twice daily, with doses twelve hours apart, as prescribed by your healthcare provider. The exact dosage and frequency depend on the type of infection being treated and your individual medical circumstances.
Q: Can voriconazole be taken with food?
A: Voriconazole should be taken as directed by your healthcare provider. Specific instructions regarding food intake will be provided with your prescription.
Q: What should I do if I miss a dose?
A: If you miss a dose, take it as soon as you remember unless it is nearly time for your next scheduled dose. Do not double doses. Contact your healthcare provider or pharmacist for guidance if you are unsure.
Q: How long does treatment with voriconazole typically last?
A: The duration of voriconazole treatment depends on the type and severity of the fungal infection being treated. Treatment should be as short as possible while remaining effective. Your healthcare provider will determine the appropriate treatment duration for your specific condition.
Q: Can I stop taking voriconazole if I feel better?
A: No, you should not discontinue voriconazole without consulting your healthcare provider, even if you feel better. Stopping treatment prematurely may result in the infection returning or worsening. Your healthcare provider will advise when it is safe to discontinue the medication.
Q: What should I do if I experience a severe allergic reaction?
A: Seek immediate medical attention if you experience symptoms of a severe allergic reaction, such as difficulty breathing, chest tightness, or severe rash. Call emergency services or go to the nearest emergency room immediately.
Q: Are there any activities I should avoid while taking voriconazole?
A: Due to the risk of photosensitivity, you should avoid prolonged exposure to sunlight and use protective clothing and sunscreen. Avoid any activities that might expose you to additional light sensitivity risks. Consult your healthcare provider for specific recommendations based on your individual circumstances.
References
- VFEND® (voriconazole) Prescribing Information — Pfizer Inc. 2025. https://labeling.pfizer.com/ShowLabeling.aspx?id=12292
- VFEND® (voriconazole) Warnings and Precautions — Pfizer Medical. 2025. https://www.pfizermedical.com/patient/vfend/warnings
- Vfend (European Medicines Agency Assessment Report) — European Medicines Agency. 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/vfend
- VFEND, INN-voriconazole (Summary of Product Characteristics) — European Commission Health. 2021. https://ec.europa.eu/health/documents/community-register/2021/20210326151197/anx_151197_en.pdf
- VFEND® (voriconazole) Patient Counseling Information — Pfizer Medical. 2025. https://www.pfizermedical.com/vfend/info-for-patient
- VFEND (voriconazole) FDA Prescribing Information Highlights — U.S. Food and Drug Administration. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021266s057,021267s067,021630s047lbl.pdf
Similar Articles
Read full bio of medha deb
